Pharma Business – October 8, 2026
Finnish Orion Pharma has signed an agreement with Qilu Pharma Europe for a pembrolizumab biosimilar for the European market. A day earlier, it dosed the first patient with ODM-216, its first biologic drug candidate to reach clinical testing.
Pharma Business – October 8, 2026
Bavarian Nordic has raised its full-year 2026 guidance for the third time this year. It now expects revenue of about DKK 6,100 million, up from about DKK 5,700 million, driven by higher sales of rabies vaccines, mainly in the US.
Pharma Business – October 8, 2026
Norwegian Prime Minister Jonas Gahr Støre will officially open Thor Medical’s AlphaOne production facility at Herøya Industrial Park on October 19. The Oslo-based company supplies high-purity alpha-emitting isotopes to the radiopharmaceutical industry.
Collaboration – October 8, 2026
Aiforia has announced a commercial agreement with PathAI, a member of the Roche Group.
Science Award – October 7, 2026
Henri B. Kagan and Kenso Soai are awarded the Nobel Prize in Chemistry 2026 for discovering how chemical reactions can produce only one of two mirror-image molecules. Their work shows how this kind of asymmetry can arise, and has been decisive for chemists designing reactions to make pharmaceuticals.
In a new job – October 7, 2026
After twelve years leading Norway’s oldest health cluster, Ketil Widerberg is leaving Oslo Cancer Cluster to head an AI initiative in healthcare at Oslo University Hospital.
Clinical Trials – October 7, 2026
Stockholm-based Pharmability has dosed the first patient in its Phase Ib study of TIR-C in atopic dermatitis, and the first cohort is now fully enrolled. The trial is the first in which the drug candidate is tested in humans.
Clinical Trials – October 7, 2026
Genmab and AbbVie’s bispecific antibody epcoritamab, added to standard R-CHOP chemoimmunotherapy, significantly improved progression-free survival in the Phase III EPCORE DLBCL-2 trial in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The companies say it is the first Phase III study of a bispecific antibody combination to show such a benefit in the frontline setting.
Clinical Trials – October 6, 2026
Boehringer Ingelheim’s survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.
Clinical Trials – October 6, 2026
Lundbeck has randomized the first patient in the Phase II DARE2 trial of its oral Parkinson’s candidate Lu AF28996. In an interview with NLS, Tarek Samad, Head of R&D, explains what the trial needs to show to justify Phase III and where the drug could fit alongside existing treatments.
Clinical Trials – October 3, 2026
Genmab has reported Phase 2 results for its antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% among 109 treated patients.
Clinical Trials – October 3, 2026
Lundbeck has reported headline results from the Phase IV THRIVE trial, in which 60% of migraine patients who had responded inadequately to a prior CGRP-targeting preventive therapy reported being “much” or “very much” improved after 24 weeks on Vyepti (eptinezumab).
PharmaRelations
Are you a people-oriented Quality Assurance professional with a passion for business development, customer relationships and building successful teams?
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
PharmaRelations
PharmaRelations is the Nordic market leader within talent services for the life science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region. We add value to our clients and candidates with our consultancy services, outsourcing solutions and recruitment of specialists and leaders.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
Stillingen er 100 % remote med en forventet arbejdsbelastning på ca. 0-20 timer pr. måned, afhængigt af projektbehov.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
In a new job – October 5, 2026
Alligator Bioscience has appointed its CFO, Johan Giléus, as CEO, effective January 1, 2027. He succeeds Søren Bregenholt, who will remain in the role until the end of the year.
In a new job – September 21, 2026
Bavarian Nordic has appointed Tarja Stenvall as President and Chief Executive Officer, effective 15 October. She succeeds Paul Chaplin, whose departure was announced earlier this year.
In a new job – September 17, 2026
Over the course of her career, Anna Sundin has worked on numerous transactions spanning capital raises, IPOs, M&A, and debt financing, as well as providing strategic advice to companies in a growth phase.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – July 19, 2026
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Profiles in Business – September 30, 2026
Trine Bartholdy has spent her career at the intersection of science and finance, helping early discoveries grow into companies capable of shaping the future of health. Now, as AI and global competition are reshaping the conditions for European life sciences, she and her colleagues at the BioInnovation Institute (BII) leverage decades of expertise to usher young Nordic companies toward entrepreneurial success.
Profiles in Business – September 24, 2026
As HealthCap marks 30 years of life science investing, co-founder Björn Odlander reflects on the firm’s long-term approach, the journey from lab to patient, and Europe’s widening capital gap.
Biotech Business – October 6, 2026
Icelandic biosimilar developer Alvotech has signed a long-term manufacturing agreement with LOTTE Biologics for US-based production. A day earlier, the FDA approved a second production suite in Reykjavik for its Humira biosimilar SIMLANDI.
Biotech Business – October 6, 2026
Beactica Therapeutics has selected BEA-28 as a preclinical candidate in its TEAD program, which aims to develop new therapies for aggressive, hard-to-treat solid tumors, including cancers that have become resistant to existing treatments.
Global report – October 6, 2026
AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company’s workforce in the state by more than 50%.
MedTech Business – October 5, 2026
Bergen-based Lifecare has manufactured its first functional continuous glucose monitoring (CGM) implants through its own operations, rather than through an external contract manufacturer. The company calls it an important step toward controlled manufacturing of its implantable sensor technology.
Collaboration – October 5, 2026
FluoGuide has entered a collaboration with medical technology company Leica Microsystems to advance precision surgery for brain tumors by combining its lead product, FG001, with Leica’s surgical microscope systems.
Financing – October 1, 2026
Umeå-based biotech Omnio has raised EUR 2.9 million in an oversubscribed round from existing investors and shareholders. The funding will move the company’s plasminogen-based therapy for hard-to-heal chronic wounds closer to clinical trials, with patient studies planned for 2027.
Biotech article – October 1, 2026
Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.
Biotech Business – October 1, 2026
Hansa Biopharma has signed a collaboration with Amsterdam-based Cradle. Hansa will use Cradle’s AI-driven protein design and engineering platform across its research and development work to develop new immunomodulatory treatments for severe autoimmune diseases.
Biotech Business – September 24, 2026
Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.
Science Award – October 5, 2026
The Nobel Assembly at Karolinska Institutet has decided to award the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.
Science News – October 5, 2026
Disrupted regulation of the hormone aldosterone is one of the main causes of resistant hypertension, according to a large genetic study led by Amgen deCODE genetics. The findings suggest more patients could benefit from drugs that block aldosterone.
Science Award – October 2, 2026
It is once again time to honor extraordinary scientific discoveries. Will it be the GLP-1 pioneers – among them Denmark’s Jens Juul Holst – optical coherence tomography, the wakefulness peptide orexin, or precision gene editing that is honored this year? Or will it be something completely different?
This site uses cookies
